Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06): a Multicenter, Randomized, Phase 2 Study

This study will evaluate the efficacy and safety of Oncolytic virus H101 combined with lenvatinib plus Toripalimab compared with FOLFOX in patients with advanced biliary tract cancer (BTC) who have progressed after first-line treatment.

Start Date01 May 2025

Sponsor / Collaborator

Fudan University

NCT06196671

/ Not yet recruitingPhase 2IIT

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

The purpose of this study is to evaluate the efficacy of oncolytic virus plus PD-1 inhibitor to Patients with Advanced Pancreatic Cancer.

Start Date01 Dec 2024

Sponsor / Collaborator

Fudan University

NCT06685354

/ Not yet recruitingPhase 2IIT

Sequential Targeted and Immunotherapy With Recombined Human Type 5 Adenovirus Via Hepatic Arterial Infusion for BCLC Stage C Hepatocellular Carcinoma: A Prospective Single-Center Single-Arm Pilot Study

Indication: Hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) stage C.
Study Objectives: This study aims to use a prospective single-center single-arm pilot approach to preliminarily obtain data on the recent efficacy and safety of sequential targeted and immunotherapy with recombinant human type 5 adenovirus (H101) administered via hepatic arterial infusion for BCLC stage C HCC. Additionally, it will explore changes in the patients' immune systems before and after treatment, providing a basis for formal research.
Study Content: The study will use a prospective single-center single-arm pilot design to preliminarily assess the efficacy of sequential targeted and immunotherapy with H101 via hepatic arterial infusion in BCLC stage C HCC. Primary efficacy endpoints include: Objective Response Rate (ORR). Secondary efficacy endpoints include: Disease Control Rate (DCR), Duration of Response (DOR), Progression-Free Survival (PFS) at 6 months and 12 months, Overall Survival (OS) at 6 months and 12 months, Median Progression-Free Survival (mPFS), Liver-specific PFS. Additionally, the study will collect data on safety and tolerability and will explore changes in peripheral blood lymphocytes before and after treatment.
Expected Objectives: Efficacy and Safety Assessment: To preliminarily gather data on the short-term efficacy, safety, and tolerability of sequential targeted and immunotherapy using hepatic arterial infusion of H101 in patients with BCLC stage C HCC. This includes assessing primary efficacy endpoints (e.g., objective response rate) and secondary efficacy endpoints (e.g., disease control rate, duration of response, progression-free survival, overall survival, etc.). Immune System Changes: To investigate the patterns of peripheral blood lymphocyte changes before and after treatment.

Start Date01 Nov 2024

Sponsor / Collaborator

Henan Cancer Hospital

100 Clinical Results associated with Recombinant human adenovirus type 5 (Sunway Biotech)

100 Translational Medicine associated with Recombinant human adenovirus type 5 (Sunway Biotech)

100 Patents (Medical) associated with Recombinant human adenovirus type 5 (Sunway Biotech)

Literatures (Medical) associated with Recombinant human adenovirus type 5 (Sunway Biotech)

06 May 2025·Anti-Cancer Agents in Medicinal Chemistry

Talimogene Laherparepvec (T-VEC): Expanding Horizons in Oncolytic Viral Therapy Across Multiple Cancer Types

Article

Author: Yap, Yeannie Hui-Yeng ; Tan, Run-Bin

Abstract::

Talimogene laherparepvec (T-VEC), the first FDA-approved oncolytic viral therapy, has transformed cancer immunotherapy since its 2015 approval for unresectable melanoma. Engineered from Herpes Simplex Virus type 1 (HSV-1) with deletions in ICP34.5 and ICP47 genes and GM-CSF insertion, T-VEC selectively replicates within the tumor cells, inducing lysis and releasing tumor-derived antigens while stimulating systemic antitumor immunity through dendritic cell activation. Although extensively studied for melanoma, its potential extends beyond this malignancy, with emerging applications in breast cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and other solid tumors. This review synthesizes T-VEC’s mechanism of action, leveraging dysregulated Ras signalling, impaired interferon pathways in cancer cells, its clinical outcomes, and safety profile across these indications. While prior literature emphasizes melanoma monotherapy and combinations with immune checkpoint inhibitors, less attention has been given to its efficacy in non-melanoma cancers and synergistic potential with chemotherapy or radiation therapy. By exploring recent trials, such as T-VEC with neoadjuvant chemotherapy in triple-negative breast cancer and pembrolizumab in HNSCC, highlighting its versatility. Comparative analysis with other oncolytic viruses like HF-10, oncorine (H101), and measles virus variants positions T-VEC within the virotherapy landscape. Key challenges—systemic delivery, immune clearance, and biomarker development for patient selection—are addressed alongside strategies to enhance immune modulation through novel combinations. This review underscores T-VEC’s expanding role in cancer treatment, offering clinicians’ and researchers’ insights to optimize its therapeutic horizons across diverse malignancies.

01 Jan 2025·ONCOLOGY RESEARCH

Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells

Article

Author: He, Yedie ; Cai, Zhijian ; Wang, Hua ; Xu, Yipeng ; Qiao, Chenxiao

Objective:

To investigate the anti-tumor effects of an E1B55KD-deleted oncolytic adenovirus, H101, in combination with a humanized anti-PD-1 (Programmed cell death protein 1) monoclonal antibody, Camrelizumab.

Methods:

Anti-tumor efficacy of intratumoral injection of H101 or/and intraperitoneal injection of Camrelizumab were evaluated in an immune system humanized NOD Prkdc ^scid Il2rg ^-/- mice subcutaneous (S.C.) tumor model, established with human glioblastoma of unknown origin cell line U87-MG, and human bladder cancer cell line T24 and YTS-1. The mechanism by which H101 induced anti-tumor immunity were also investigated.

Results:

Combining H101 with Camrelizumab demonstrated more potent anti-tumor effects than monotherapy in mouse S.C. tumor model. Increased tumor-infiltrating T cells were observed in the combined treatment group. H101 infection decreased the expression of CD47 in cancer cells, thereby promoting macrophages to phagocytose cancer cells. Following the H101-mediated activation of macrophages, increased levels of cytokines, including TNF, IL-12 and IFN-γ were observed. Moreover, when induced THP-1 cells were co-cultured with H101-treated cancer cells, expression of IFN-γ was increased in T cells. Elimination of IL-12 using an anti-IL-12 antibody abolished IFN-γ production from T cells. In addition, infection with H101 increased PD-L1 expression in YTS-1 cells. These results suggested that H101 may act synergistically to enhance the therapeutic efficacy of PD-1 blockade in cancer via suppressing CD47 signaling, which may promote macrophages to phagocytose tumor cells and activate CD8⁺ T cells.

Conclusion:

The combination of H101 with PD-1 blockade exhibits potential as a novel strategy for the treatment of cancer.

01 Dec 2024·ACTA PHARMACOLOGICA SINICA

Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells

Article

Author: Li, Meng-Kai ; Zhong, Yu-Wen ; Sun, Lei ; Duan, Shi-Xin ; Qiao, Yu ; Wang, Zi-Shu ; Lou, Xin-Yi ; Qian, Feng ; Yang, Xin-Yi ; Wang, Zhi-Ming ; Yang, Qing-Ling ; Liu, Ying

Recombinant human type 5 adenovirus (H101) is an oncolytic virus used to treat nasopharyngeal carcinoma. Owing to the deletion of the E1B-55kD and E3 regions, H101 is believed to selectively inhibit nasopharyngeal carcinoma. Whether H101 inhibits other type of tumors via different mechanisms remains unclear. In this study we investigated the effects of H101 on melanomas. We established B16F10 melanoma xenograft mouse model, and treated the mice with H101 (1 × 10⁸ TCID₅₀) via intratumoral injection for five consecutive days. We found that H101 treatment significantly inhibited B16F10 melanoma growth in the mice. H101 treatment significantly increased the infiltration of CD8⁺ T cells and reduced the proportion of M2-type macrophages. We demonstrated that H101 exhibited low cytotoxicity against B16F10 cells, but the endothelial cells were more sensitive to H101 treatment. H101 induced endothelial cell pyroptosis in a caspase-1/GSDMD-dependent manner. Furthermore, we showed that the combination of H101 with the immune checkpoint inhibitor PD-L1 antibody (10 mg/kg, i.p., every three days for three times) exerted synergic suppression on B16F10 tumor growth in the mice. This study demonstrates that, in addition to oncolysis, H101 inhibits melanoma growth by promoting anti-tumor immunity and inducing pyroptosis of vascular endothelial cells.

News (Medical) associated with Recombinant human adenovirus type 5 (Sunway Biotech)

22 May 2024

·www.biospace.com

Global Oncolytic Virus Immunotherapy Clinical Trials Landscape

“Currently More Than 180 Oncolytic Virus Immunotherapies Are In Clinical Trials” Conventionally, the management of cancer was predominantly restricted to surgery, radiation therapy, in addition to chemotherapy. Even though these therapies have shown significant abolition of primary tumors, their allied systemic toxicities and the high incidences of relapse are the foremost limitations. The escalation in prevalence of cancer and the curbs of conventional therapies have propelled the demand of novel targeted therapies which can overcome the limitations and have enhanced specificity and target ability towards the disease. One such approach is using the virus as a therapeutic approach to deliver cancer fighting genes to the tumor cell and thereby inducing an immuno modularity response that will aid to cause death in cancerous cell. This led the development of oncolytic virus therapy as a promising treatment to cure rising cancer malignancies. The oncolytic virus therapy clenches long history which can be backpedalled the late 1950s to 1970s epoch in which the multiple clinical trials and studies were ongoing with the wild type viruses in order to understand a novel approach to treat tumor cells. Moreover, oncolytic viral therapy provides enormous advantage such as higher response towards cancer cells owing to the presence of impaired antiviral defense in addition to better delivery of therapeutic payloads to tumor cells as compared to the conventional treatment which aims to reduce or delays the symptoms of cancer. Download Oncolytic Virus Immunotherapies Clinical Trials Landscape Research: The research and development picked up its pace ever since the oncolytic virus therapy called Oncorine was approved by the National Medical Products Administration (NMPA) to treat Head and neck cancer in the year 2005. However, the drug was only accessible in China owing to the strict rules and regulations. Nevertheless, the approval of Oncorine has provided surplus thrust to the research and development across the globe which led to the approval by FDA for the first viral therapy, T- VEC (Imlygic) to treat melanoma. One of the primary impetuses for the growth of oncolytic virus therapy domain was due to the rising ascendancy of these therapies in the clinical studies. Preliminary data from the clinical trial studies demonstrates that more than 150 clinical researches are currently ongoing for the treatment of innumerable seldom and common diseases such as Alzheimer disease, herpes simplex 1, advanced biliary tract cancer, chronic hepatitis b, refractory malignant ascites as well as hepatocellular carcinoma. The clinical pipeline for the domain of viral therapy is mounting at an incredible gait. For instance, a modified human recombinant type 5 adenovirus with genetic modifications H101 is a novel treatment regimen used to provide treatment for patients suffering from advanced biliary tract cancer. The study is lately in the phase I clinical stage which is sponsored and collaborated by Fudan University. To further enhanced in addition to improve the efficacy, novel viral oncolytic therapy are used in combination with other drugs with the purpose to provide improved and advanced treatment regimen to the patients suffering from cancer. For instance, a novel Telomerase-specific Type 5 Adenovirus OBP-301 viral therapy in conjugation with Carboplatin, Paclitaxel as well as radiation therapy is used to cure adenocarcinoma. The clinical studies in lately in the phase I clinical stage which is sponsored and collaborated by NRG Oncology and National Cancer Institute (NCI). Researches believed that the oncolytic virus therapy clench potential as well as long lasting promising therapeutic effects. As a consequence, multiple pharmaceutical companies along with centers such as City of Hope Comprehensive Cancer Center, New York Medical College, Children's Hospital of Pennsylvania, Mayo Clinic in Arizona, Peking University First Hospital as well as Beijing Tiantan Hospital, Capital Medical University are working recklessly for the purpose to develop advanced oncolytic virus therapy that controls the prognosis of cancer diseases along with other indications such as advanced bladder carcinoma, pancreatic cancer, solid tumor and gastrointestinal cancer. All these examples mentioned above demonstrate that the clinical and translational market for oncolytic virus therapy is growing at an absurd pace.

Phase 1ImmunotherapyDrug ApprovalVaccine

20 Dec 2022

·www.prnewswire.com

Worldwide Oncolytic Virus Immunotherapy Industry to 2028 - Outlook on More Than 180 Oncolytic Virus Immunotherapies in Clinical Trials

DUBLIN, Dec. 20, 2022 /PRNewswire/ -- The "Global Oncolytic Virus Immunotherapy Market and Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global cancer immunotherapy market encompasses a broad range of applications, in which oncolytic virus immunotherapy is playing a vital role in overall development. Report Highlights Global Oncolytic Virus Immunotherapy Therapy Market Overview Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1 Billion By 2028 Insight On More Than 180 Oncolytic Virus Immunotherapies In Clinical Trials Patent Information On More Than 60 Therapies in Clinical Trials IMLYGIC, Oncorine, Delytact: Availability, Dosage, and Price Analysis Oncolytic Virus Immunotherapy Clinical Pipeline By Country, Phase, Indication, Organization, Patient Segment Oncolytic Virus Immunotherapy Application By 10 Cancer Recent Strategic Partnerships, Collaborations, Mergers and Acquisitions The therapy involves a very basic thread of using viruses for targeting cancer cells and harnessing the natural as well as the destructive power of the immune system against the cancer cells. In a very short period of time, the clinical outcome associated with the therapy has laid down the foundation for the over-achieving future of the therapy. The therapy market is estimated to get recognized as a necessity in the overall cancer therapeutics market where old and traditional therapies available are not successful in declining the increasing mortality rate across the globe. Researchers have been successful in modifying the basic immunotherapy strategy by introducing the benefits of viruses in targeting the host cells. Beyond the excellent capacity of the virus to get incorporated into the host cell, the therapeutic introduction of the virus in cancer therapeutics is providing enormous amounts of opportunities that were somehow lacking in the overall cancer therapeutics market for a prolonged period of time. The future approval of the oncolytic virus therapy against a wide range of cancer types is believed to strengthen the pharmaceutical industry to reach the revenue sales that have not been recorded for any of the cancer therapy drugs. The strong link of the therapy with the clinical pipeline and the future timeframe which is about to justify the applications of the therapy are observed to overcome the challenges that the researchers have been facing in terms of resistance development, off-targeting, and adverse side effects. Amid the growth of other cancer therapies in the cancer therapeutics market, oncolytic virus therapy soon is going to deliver significant revolution and growth. The unimaginable applications of the therapy and the orientation of the government bodies towards expanding the clinical trial market of the same is estimated to develop the market as a dominant one for millions of patients who haven't received any benefits from the available therapies. The entry of oncolytic virus therapy into the market horizon is estimated to provide enormous healthcare opportunities to patients who have been struggling with cancer for a prolonged period of time. As per the report findings, the overall appreciation that the therapy has achieved in the such a shorter time period is poised to incline the therapy towards substantial growth. In the coming time period, the therapy market is believed to deliver promising trends and opportunities for researchers working in different biopharmaceutical companies and research centers, with hundreds of driving forces driving the market through various complications. On the regulatory side, the legislations of developed pharmaceutical countries are also inclining towards boosting the researchers to expand the market applications and drive the competition in the right direction, where appropriate funds for clinical research activities are acting as the catalyst for the therapy. The unlimited applications found within the therapy and the clinical platform for the same is estimated to move the therapy toward success at an unprecedented rate in the coming years. Key Topics Covered: 1. Introduction to Oncolytic Virus: Trail From Genesis To Biogenetics 2. Primer of Virotherapy in Malignancies 2.1 Oncolytic Viruses Towards Cancer 2.2 Approaches for Targeting Tumor Cells 2.3 Viral Oncolysis Mechanism of Action 3. Oncolytic Viruses Immunotherapy Overview 3.1 Stimulation of Antitumor Immune Responses 3.2 Oncolytic Viruses as Cancer Vaccines 4. Potential Oncolytic Virus Immunotherapy for Cancers 4.1 Breast Cancer 4.2 Lung Cancer 4.3 Prostate Cancer 4.4 Melanoma 4.5 Brain Tumor 4.6 Blood Cancer 4.7 Colorectal Cancer 4.8 Bladder Cancer 4.9 Pancreatic Cancer 4.10 Head and Neck Cancer 5. Global Oncolytic Virus Immunotherapy Therapy Market Overview 5.1 Preface Towards Oncolytic Virus Arcade 5.2 Market Aspects of Approved Oncolytic Viruses 6. Imlygic (Talimogene laherparepvec): Clinical and Pricing Insight 6.1 Clinical Overview 6.2 Availability, Dosage and Price Analysis 7. Oncorine (H101): Clinical and Pricing Insight 7.1 Clinical Overview 7.2 Availability, Dosage and Price Analysis 8. Delytact (DS 1647): ): Clinical and Pricing Insight 8.1 Clinical Overview 8.2 Availability, Dosage and Price Analysis 9. Global Oncolytic Virus Immunotherapy Clinical Pipeline Overview 9.1 By Phase 9.2 By Company 9.3 By Country 9.4 By Indication 9.5 By Patient Segment 10. Global Oncolytic Viruses Clinical Pipeline By Company, Indication and Phase 10.1 Research 10.2 Preclinical 10.3 Phase-I 10.4 Phase-I/II 10.5 Phase-II 10.6 Phase-III 10.7 Registered 11. Strategic Partnerships, Collaborations, Mergers and Acquisitions to Advance the Oncolytic Virus Therapy Market 11.1 Estrella Biopharma Signs Deal To Merge With Blank Check Company 11.2 ABL and Imugene Announce Partnership to Advance Oncolytic Virus Candidates Into Late Clinical Trial Phase 11.3 TILT Biotherapeutics and Merck to Undergo Clinical Trial Collaboration for Refractory Non-Small Cell Lung Cancer 11.4 Virogin Biotech and MD Anderson Announce Strategic Collaboration For Treating Advance Cancers 11.5 ABL Signs Pact With KaliVir On Oncolytic Viruses 11.6 Targovax Announces Clinical Collaboration With Agenus For Melanoma Trial 11.7 KaliVir Announces Exclusive Agreement With Roche For Developing Novel Oncolytic Viruses 11.8 ImmVira and Roche Enter Cooperation Agreement For Evaluating Novel Combination For Cancer Therapy 11.9 Calidi and Edoc Agree On Merger To Revolutionize Oncolytic Viral Therapies 11.10 Synthetic Biologics Completes Acquisition of VCN Biosciences 11.11 VacV Biotherapeutics Exits Stealth With $3 Million Investment 11.12 Targovax Enters Research Collaboration With Karolinska Institutet Professor 11.13 Transgene and PersonGen To Collaborate To Evaluate New Combination Therapy Against Solid Tumors 11.14 Lokon Pharma Initiates Collaboration With To Develop Novel Cancer Therapeutics 11.15 Bionaut Labs and Candel Therapeutics Announce Collaboration For Novel Targeting Mechanism For Oncolytic Virus Delivery 11.16 Imugene and Eureka Announce Strategic Collaboration to Accelerate Oncolytic Virus and T-Cell Therapy Combination 11.17 CG Oncology Enters Into Clinical Trial Collaboration With Roche For Novel Oncolytic Immunotherapy Combination 11.18 Imugene Enters Into Exclusive Strategic Partnership With Celularity To Develop Novel Combination For Treating Solid Tumors 12. Global Oncolytic Virus Immunotherapy Market Dynamics 12.1 Favorable Market Parameters 12.2 Growth Inhibitors 13. Global Oncolytic Virus Immunotherapy Market Future Outlook 14. Competitive Landscape 14.1 AdCure Bio 14.2 Beijing SyngenTech 14.3 BioVex Inc. 14.4 Calidi Biotherapeutics 14.5 Genelux Corporation 14.6 Immvira Pharma 14.7 Jennerex Biotherapeutics 14.8 KaliVir 14.9 Lokon Pharma 14.10 Merck 14.11 Oncolys BioPharma 14.12 Oncorus 14.13 PsiOxus Therapeutics 14.14 Seneca Therapeutics 14.15 Shanghai Sunway Biotech 14.16 Takara Bio 14.17 Targovax 14.18 TILT Biotherapeutics 14.19 Transgene 14.20 Virogin Biotech For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

ImmunotherapyAcquisitionClinical Study

15 Apr 2021

·www.globenewswire.com

Global Oncolytic Virus Therapies Market: Focus on

New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region, and Competitive Landscape - Analysis and Forecast, 2020-2030" - • Commercialized Therapies: Imlygic, Oncorine, and RIGVIR• Pipeline Therapies: Phase I, Phase II, Phase III, Phase IV• Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild-Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)• Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)Regional Segmentation• North America: U.S.• Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)• Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)Growth Drivers• Increasing Incidence of Cancer• Rising Number of Clinical Trials• Increasing Research Funding from National Cancer Institute• Increasing Adoption of Inorganic Growth Strategies in the MarketMarket Challenges• High Cost of Therapy• Lack of Therapy-Specific AssaysMarket Opportunities• Opportunities in the Emerging Economies• Drug Approvals and Strong Pipeline of Oncolytic Virus TherapiesKey Companies ProfiledAmgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.Key Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?• What are the key development strategies being implemented by the major players in order to sustain in the competitive market? • What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030?• Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?• What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world? • What is the COVID-19 impact on the global oncolytic virus therapies market?• Which companies are anticipated to be highly disruptive in the future, and why?• What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?• What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?• What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types: o Commercialized Therapies o Pipeline Therapies o Type of Virus o Application o RegionMarket OverviewOncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body.These therapies aim at modifying genetic material for the treatment of a disease.Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”.Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth.Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay.Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.Countries Covered• North America• U.S.• Europe• U.K.• Latvia• Georgia• Armenia• Germany• France• Italy• Rest-of-Europe• Asia-Pacific• China• Japan• Rest-of-APACRead the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________

Gene Therapy

100 Deals associated with Recombinant human adenovirus type 5 (Sunway Biotech)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XX	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nasopharyngeal Carcinoma	China	Shanghai Sunway Biotech Co., Ltd.	01 Nov 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malignant ascites	Phase 2	China	Fudan University	05 Mar 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05051696 (ESMO 12023 \| ESMO 22023) Manual	Phase 2	Uterine Cervical Cancer	49	H101	vylxaiorah(jnhsuqetap) = pexaypjlaf ungroinsfq (jbjrovdxhn, 60.7 - 86.3) View more	Positive	22 Oct 2023
ESMO2023	Not Applicable	Neoplasms	653	H101 monotherapy	tsdcwocdfb(xuvosybazl) = nxjqtpsrql wzupcgafjr (jnfqfgxsxx )	Positive	21 Oct 2023
ESMO2023	Not Applicable	Neoplasms	653	H101 combined with chemotherapy	tsdcwocdfb(xuvosybazl) = dmtezcdgbp wzupcgafjr (jnfqfgxsxx )	Positive	21 Oct 2023
CA209-7CE (ESMO_IO2022) Manual	Phase 2	Advanced Hepatocellular Carcinoma	18	H101 2 vials+Nivolumab 3mg/kg	uhgfbrguko(eczvzwclet) = cdsjjdbbqn wsktzimvgf (zdhdkoxptn ) View more	Positive	08 Dec 2022
H101 phase II clinical trial (ASCO2006)	Phase 2	Advanced cancer	106	H101 alone	crarmmgntm(dcrjqalurd) = eznkdlmulr ynoptbnvtu (rcfuzkdayn )	Positive	20 Jun 2006
H101 phase II clinical trial (ASCO2006)	Phase 2	Advanced cancer	106	H101 combined with conventional chemotherapy	crarmmgntm(dcrjqalurd) = nxeykltpil ynoptbnvtu (rcfuzkdayn )	Positive	20 Jun 2006

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis